CACLP 2022 Booth No.: A4-2109

Pointe Biotech (Nanjing) Co., Ltd. (hereinafter referred to as: Pointe) and its shareholders formally reached a strategic consensus and completed the signing of the contract, YHLO will hold 52.64% of Pointe` s equity by acquiring part of Pointe' s equity and increasing its capital, Pointe will also become a controlling subsidiary of YHLO.

Pointe was established in 2002. Since the beginning, as a professional in vitro diagnostics enterprise, Pointe is committed to providing high quality in vitro diagnostic products and services for customers and becomes a trustworthy IVD products provider.

Till now, Pointe has established one wholly-owned subsidiary and over 100 distributors and more than 120 corporate customers spread around China. The nationwide network ensures Pointe have an insight into market trends and immediately response to customers' demands.

In 2005, the company has formally established the R&D center for in vitro diagnostics reagents. The R&D team perseveres in improving the quality to provide end-users with more qualified and accurate products. We truely believe that prevention is better than cure. Therefore, in the course of more than a decade of R&D, we continuously develop the products with more sensitive, accurate results which indicate the disease earlier.

Since the establishment, Pointe believes that the excellent quality is the essence of products. To this end, the company has exceeded in the Quality Management System Assessments conducted by Jiangsu Food and Drug Administration, and was accredited with YY/T 0287 idt IOS 13458:2003 and GB/T19001 idt ISO 9001:2008 Quality Management System Certifications since 2007. Currently, the company obtains 81 registration licenses for reagents. Comprehensive quality management system, efficient quality control measures and standardized production operating procedures ensures the best quality of products.

“Integrity, collaboration and shared success” is Pointe’s motto, meanwhile, it’s also the company’s core value. Pointe is devoted itself to be a reliable partner in IVD field.

About YHLO:

YHLO (EST. 2008) is an innovative and steadfastly growing company of immunoassay solutions headquartered in Shenzhen, China, specialized in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents by a team of experienced scientists and engineers. In May of 2021, YHLO has successfully launched IPO and listed on Shanghai Stock Exchange (Stock code: 688575). As a national high-tech enterprise with many intellectual properties, YHLO’s mission is to "Focus on Healthcare, Better Life with Technology".